Physician Education: Bridging Clinical Research and Patient Care

Faculty Profile

Professor of Medicine, Epidemiology, and Public Health
Yale University School of Medicine
New Haven, Connecticut

Topics of Professional Interest:
  • Adherence to antiretroviral therapy
  • HIV care in marginalized populations
  • HIV prevention in clinical care settings
  • Interactions between antiretroviral therapies and methadone
  • HIV and injection drug use
  • Antiretroviral therapy in the developing world
Current Professional Summary:

Dr Friedland is Director of the Yale AIDS care program, Yale-New Haven Hospital, and Professor of Medicine, Epidemiology and Public Health, Yale School of Medicine. He is involved in clinical care, teaching, and clinical research in HIV therapy and prevention.

Committees and Organizations:
  • National Institute on Drug Abuse, National Advisory Council Office of AIDS Research Advisory Council Steering Committee and Scientific Program Committee, Community Program for Clinical Research on AIDS (CPCRA)
  • New Haven Mayor's Task Force on AIDS
Honors and Awards:
  • Connecticut AIDS Leadership Award
  • New York State AIDS Leadership Award
  • Pacesetter Award, National Institute on Drug Abuse
  • Award for Excellence, AIDS Project New Haven
Education:
  • Columbia College, BA, History and Sociology (1959)
  • New York University School of Medicine, MD (1964)
  • Bellevue Hospital, New York City, Internship and Residency (1965, 1967–1968)
  • Beth Israel Hospital, Boston, Fellow in Infectious Diseases (1968–1970)
Selected Publications:
  1. Wainberg MA, Friedland GH. Public health implications of antiretroviral therapy and drug resistance. JAMA. 1998;279:1997-1983.
  2. McCancey-Katz EF, Rainey P, Tatlow P, Friedland GH. Methadone effects on zidovadine disposition, JAIDS. 1998;18:435-443.
  3. Altice FL, Friedland GH. The era of adherence to antiretroviral therapy. Ann Intern Med. 1998;129:503-505.
  4. Lin PF, Gonzalez CG, Griffin B, Friedland GH, et al. Stavudine resistance. Antiretroviral Therapy. 1999;4:21-28.
  5. Friedland GH, Pollard R, Griffith B, et al. The efficacy and safety of delavirdine mesylate in combination with zidovudine and didanosine. (ACTG261). JAIDS. 1999;21:281-292.
  6. Friedland GH, Williams AB. The future: attaining higher goals in HIV treatment: the central importance of adherence. AIDS. 1999;13 (suppl):561-572.
  7. Altice FL, Friedland GH, Loobey E. Nevirapine induced opiate withdrawal among injection drug users with HIV receiving methadone. AIDS. 1999;13:957-962.
  8. Rainey P, Friedland GH, McCancey EF, et al. Interaction of methadone with didanosine (ddI) and stavudine (d4T). JAIDS. 2000;24:241-248.
  9. Friedland GH. Breaking the silence. AIDS Clinical Care. 2000;12:69-71.
  10. Friedland GH. Issues in HIV therapy in "triple diagnosed" patients. Top HIV Med. 2000;8:14-18.

Presentations

Improving the Management of HIV Disease®: An Advanced CME Live Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management

An Advanced CME Live Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management

An Advanced CME Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management